IL141868A0 - Novel methods for therapeutic vaccination - Google Patents

Novel methods for therapeutic vaccination

Info

Publication number: IL141868A0
Authority: IL; Israel
Prior art keywords: antigen; weak; analogues; antigens; immunogenic
Prior art date: 1998-10-05

Application number

IL14186899A

Other languages

English (en)

Original Assignee

M & E Biotech As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-05

Filing date

1999-10-05

Publication date

2002-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL141868(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-05 Application filed by M & E Biotech As filed Critical M & E Biotech As

2002-03-10 Publication of IL141868A0 publication Critical patent/IL141868A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL14186899A 1998-10-05 1999-10-05 Novel methods for therapeutic vaccination IL141868A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA199801261		1998-10-05
US10501198P	1998-10-20	1998-10-20
PCT/DK1999/000525 WO2000020027A2 (en)	1998-10-05	1999-10-05	Methods for therapeutic vaccination

Publications (1)

Publication Number	Publication Date
IL141868A0 true IL141868A0 (en)	2002-03-10

Family

ID=26065489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14186899A IL141868A0 (en)	1998-10-05	1999-10-05	Novel methods for therapeutic vaccination

Country Status (25)

Country	Link
US (3)	US7005498B1 (xx)
EP (1)	EP1117421B2 (xx)
JP (1)	JP2002526419A (xx)
KR (1)	KR100731820B1 (xx)
CN (1)	CN1325115C (xx)
AT (1)	ATE269100T1 (xx)
AU (1)	AU751709B2 (xx)
CA (1)	CA2345817C (xx)
CZ (1)	CZ20011049A3 (xx)
DE (1)	DE69918146T2 (xx)
EA (1)	EA003634B1 (xx)
EE (1)	EE200100203A (xx)
ES (1)	ES2222728T3 (xx)
HK (1)	HK1039749B (xx)
HR (1)	HRP20010319A2 (xx)
HU (1)	HUP0103976A3 (xx)
IL (1)	IL141868A0 (xx)
MX (1)	MXPA01003503A (xx)
NO (1)	NO20011586L (xx)
NZ (1)	NZ511055A (xx)
PL (1)	PL202399B1 (xx)
PT (1)	PT1117421E (xx)
SK (1)	SK4272001A3 (xx)
TR (1)	TR200100936T2 (xx)
WO (1)	WO2000020027A2 (xx)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1072897A (en)	1995-12-12	1997-07-03	Karolinska Innovations Ab	Peptide binding the klvff-sequence of amyloid beta
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
KR100731820B1 (ko)	1998-10-05	2007-06-25	파멕사 에이/에스	치료적 백신화를 위한 새로운 방법
US6913749B2 (en)	1998-11-02	2005-07-05	Resistentia Pharmaceuticals Ab	Immunogenic polypeptides for inducing anti-self IgE responses
US7198920B1 (en) *	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
CZ20013709A3 (cs) *	1999-04-23	2002-11-13	Pharmexa A/S	Analog interleukinu 5, fragment nukleové kyseliny, vektor, buňka, přípravky a pouľití
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6500641B1 (en) *	1999-05-06	2002-12-31	Wake Forest University School Of Medicine	Compositions and methods for identifying antigens which elicit an immune response
EA008762B1 (ru) *	2000-02-21	2007-08-31	Фармекса А/С	АНАЛОГ АУТОЛОГИЧНОГО Аβ ИЛИ АРР ЖИВОТНОГО И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CZ20022748A3 (cs)	2000-02-21	2004-03-17	Pharmexa A/S	Nová metoda regulace obsahu amyloidu
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
DE10042598A1 (de) *	2000-08-30	2002-03-28	Gsf Forschungszentrum Umwelt	Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US8435939B2 (en)	2000-09-05	2013-05-07	Biokine Therapeutics Ltd.	Polypeptide anti-HIV agent containing the same
AU2001285721A1 (en) *	2000-09-06	2002-03-22	Pharmexa A/S	Method for down-regulating IgE
AU2002210407A1 (en) *	2000-10-27	2002-05-06	Pharmexa A/S	Therapeutic vaccine formulations containing chitosan
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
WO2002066056A2 (en) *	2001-02-19	2002-08-29	Pharmexa A/S	Synthetic vaccines comprising polyhydroxypolymer carriers
US7097837B2 (en)	2001-02-19	2006-08-29	Pharmexa A/S	Synthetic vaccine agents
WO2009003492A1 (en)	2007-07-03	2009-01-08	Dako Denmark A/S	Mhc multimers, methods for their generation, labeling and use
US7604955B2 (en)	2001-08-13	2009-10-20	Swey-Shen Alex Chen	Immunoglobulin E vaccines and methods of use thereof
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
WO2003059379A2 (en) *	2002-01-17	2003-07-24	Pharmexa A/S	Immunogenic carcinoembryonic antigen (cea)
US8623822B2 (en)	2002-03-01	2014-01-07	Bracco Suisse Sa	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en)	2002-03-01	2007-08-28	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
AU2003278807A1 (en)	2002-03-01	2004-08-13	Bracco International B.V.	Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en)	2002-03-01	2010-09-14	Bracco International B.V.	Targeting vector-phospholipid conjugates
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
JP2005528373A (ja) *	2002-03-26	2005-09-22	イミュネックス・コーポレーション	免疫プロトコルにＦｌｔ３リガンドを用いる方法
US20090110702A1 (en)	2002-07-12	2009-04-30	The Johns Hopkins University	Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en)	2002-07-12	2015-12-01	The Johns Hopkins University	Mesothelin vaccines and model systems
JP2006521090A (ja) *	2002-07-12	2006-09-21	ザジョンズホプキンスユニバーシティー	メゾテリンワクチンおよびモデルシステム
KR100555211B1 (ko) *	2002-07-16	2006-03-03	주식회사 팬제노믹스	항암효과를 갖는 Ｈｅｒ-２/ｎｅｕＤＮＡ 백신
AU2003261723A1 (en)	2002-08-27	2004-03-19	Takeda Chemical Industries, Ltd.	Cxcr4 antagonist and use thereof
GB0228796D0 (en) *	2002-12-11	2003-01-15	Adjuvantix Ltd	Valency
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
EP1622942B1 (en) *	2003-05-01	2014-11-19	ImClone LLC	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
TWI374893B (en)	2003-05-30	2012-10-21	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
EA008827B1 (ru) *	2003-06-25	2007-08-31	Фармекса А/С	Очистка вариантов her-2
JP4579912B2 (ja)	2003-06-25	2010-11-10	ビーエヌ・イミュノセラピューティクス・インコーポレイテッド	Ｈｅｒ−２変異体の精製
US20070014807A1 (en) *	2003-09-03	2007-01-18	Maida Anthony E Iii	Multiplex vaccine
WO2005033278A2 (en) *	2003-09-30	2005-04-14	Ludwig Institute For Cancer Research	In vivo efficacy of ny-eso-1 plus iscom
US20070184023A1 (en) *	2003-10-30	2007-08-09	Pharmexa A/S	Method for down-regulation of vegf
US20090028874A1 (en) *	2003-12-24	2009-01-29	Leiden University Medical Center	Synthetic Protein as Tumor-Specific Vaccine
US7674456B2 (en) *	2004-06-14	2010-03-09	Charles Wiseman	Breast cancer cell lines and uses thereof
US20070190072A1 (en) *	2004-09-30	2007-08-16	Csl Limited Ludwig Institute For Cancer Research	In vivo efficacy of ny-eso-1 plus adjuvant
WO2007001448A2 (en)	2004-11-04	2007-01-04	Massachusetts Institute Of Technology	Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
TW200635607A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized Aβ antibodies for use in improving cognition
AU2006228872A1 (en) *	2005-03-31	2006-10-05	Pharmexa A/S	Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope
CN100354002C (zh) *	2005-05-31	2007-12-12	中国人民解放军第三军医大学第一附属医院	一种新的以异种免疫细胞为细胞载体的细胞疫苗及其制备方法
KR101246428B1 (ko)	2005-06-17	2013-03-21	필라델피아 헬스 앤드 에듀케이션 코포레이션 디/비/에이 드렉셀 유니버시티 컬리지 오브 메디슨	항－ＰＤＧＦＲα 항체를 이용하여 이차 골 종양을 치료하는 방법
MX2007015933A (es) *	2005-06-17	2008-04-21	Mannkind Corp	Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
WO2007070682A2 (en)	2005-12-15	2007-06-21	Massachusetts Institute Of Technology	System for screening particles
WO2007085266A1 (en) *	2006-01-30	2007-08-02	Dako Denmark A/S	High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
CN101484587B (zh) *	2006-02-03	2014-02-12	英克隆有限责任公司	Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
AU2007215503A1 (en) *	2006-02-09	2007-08-23	Transtech Pharma, Inc.	Rage fusion proteins and methods of use
EP2007435B1 (en)	2006-03-31	2019-12-18	Massachusetts Institute Of Technology	System for targeted delivery of therapeutic agents
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
EA017291B1 (ru) *	2006-05-05	2012-11-30	Транстек Фарма, Инк.	Белки слияния на основе rage, их композиции и способы их применения
US8367113B2 (en)	2006-05-15	2013-02-05	Massachusetts Institute Of Technology	Polymers for functional particles
WO2007137586A2 (en) *	2006-05-31	2007-12-06	Pharmexa A/S	Random insertion of peptides
WO2007150030A2 (en) *	2006-06-23	2007-12-27	Massachusetts Institute Of Technology	Microfluidic synthesis of organic nanoparticles
NZ597998A (en) *	2006-10-06	2013-08-30	Bavarian Nordic Inc	Methods for treating cancer with mva
WO2008075371A2 (en) *	2006-12-21	2008-06-26	Biokine Therapeutics Ltd.	T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
WO2008098165A2 (en)	2007-02-09	2008-08-14	Massachusetts Institute Of Technology	Oscillating cell culture bioreactor
US20080199467A1 (en) *	2007-02-15	2008-08-21	Mjalli Adnan M M	Immunoglobulin fusion proteins and methods of making
EP2361930A3 (en)	2007-03-26	2011-10-26	Dako Denmark A/S	Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
US20090074828A1 (en) *	2007-04-04	2009-03-19	Massachusetts Institute Of Technology	Poly(amino acid) targeting moieties
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8613920B2 (en)	2007-07-27	2013-12-24	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2009023266A1 (en) *	2007-08-14	2009-02-19	Ludwig Institute For Cancer Research	Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
EP2853267B1 (en) *	2007-09-21	2016-12-07	The Regents of the University of California	Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2197908A2 (en)	2007-09-27	2010-06-23	Dako Denmark A/S	Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2620157A3 (en)	2007-10-12	2013-10-16	Massachusetts Institute of Technology	Vaccine nanotechnology
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
NZ601827A (en) *	2007-10-18	2014-01-31	Bavarian Nordic Inc	Use of mva to treat prostate cancer
US10968269B1 (en)	2008-02-28	2021-04-06	Agilent Technologies, Inc.	MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) *	2008-07-23	2020-07-28	Immudex Aps	Combinatorial analysis and repair
AU2009279365A1 (en) *	2008-08-05	2010-02-11	The University Of Queensland	Antigen-presenting scaffolds
GB0817244D0 (en) *	2008-09-20	2008-10-29	Univ Cardiff	Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en)	2008-10-02	2024-05-28	Agilent Technologies, Inc.	Molecular vaccines for infectious disease
US10369204B2 (en)	2008-10-02	2019-08-06	Dako Denmark A/S	Molecular vaccines for infectious disease
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en)	2008-10-12	2013-01-01	The Brigham And Women's Hospital, Inc.	Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en)	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US7998488B2 (en)	2008-11-14	2011-08-16	Baxter International Inc.	Vaccine formulations and uses thereof
JP5792630B2 (ja)	2009-01-28	2015-10-14	エピミューン，インコーポレイティド	Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
CN102448491A (zh)	2009-04-01	2012-05-09	迈阿密大学	疫苗组合物和其使用方法
EP2432893B1 (en) *	2009-05-19	2019-05-01	University Of Miami	Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
JP5715622B2 (ja)	2009-06-14	2015-05-07	バイオカインセラピューティックスリミテッド	血小板レベルを増大させるためのペプチド療法
BR112012000032A2 (pt)	2009-07-03	2016-03-15	Bionor Immuno As	meios terapêuticos e diagnósticos inovadores
BR112012003977A2 (pt) *	2009-08-26	2017-06-06	Selecta Biosciences Inc	composições que induzem ajuda de célula t
AU2010291900A1 (en) *	2009-09-14	2012-03-22	The Trustees Of The University Of Pennsylvania	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
WO2011119484A1 (en) *	2010-03-23	2011-09-29	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
KR102117350B1 (ko) *	2010-04-13	2020-06-02	이뮤노베이티브 테라피스, 엘티디.	조절 t 세포들의 저해를 위한 방법 및 조성물
EA030813B1 (ru)	2010-05-26	2018-10-31	Селекта Байосайенсиз, Инк	Способы генерации антительного иммунного ответа и увеличения местной индукции иммунных цитокинов при использовании синтетических наноносителей, соединенных с адъювантами
US9994443B2 (en)	2010-11-05	2018-06-12	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
CN106434676B (zh) *	2010-11-12	2020-10-23	宾夕法尼亚大学托管会	共有前列腺抗原、编码所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途
WO2012092934A1 (en)	2011-01-06	2012-07-12	Bionor Immuno As	Monomeric and multimeric immunogenic peptides
CN102716472A (zh) *	2011-03-31	2012-10-10	李光辉	一种肿瘤疫苗及其合成方法
CN107693798A (zh)	2011-04-29	2018-02-16	西莱克塔生物科技公司	用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体
SG10201604236RA (en) *	2011-05-26	2016-07-28	Geneius Biotechnology Investments Llc	Modulated Immunodominance Therapy
CN103702687A (zh)	2011-07-29	2014-04-02	西莱克塔生物科技公司	产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
WO2013040015A2 (en) *	2011-09-13	2013-03-21	Immunotope, Inc.	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN103063836B (zh) *	2011-10-18	2016-03-30	复旦大学附属华山医院	检测分枝杆菌感染的试剂、方法和试剂盒
CA2864841C (en)	2012-02-17	2020-07-07	Keith L. Knutson	Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide
US9439942B2 (en)	2012-04-24	2016-09-13	Biokine Therapeutics Ltd.	Peptides and use thereof in the treatment of large cell lung cancer
PT2844282T (pt)	2012-05-04	2019-07-23	Pfizer	Antigénios associados à próstata e regimes de imunoterapêutica baseados em vacinas
KR20150029678A (ko)	2012-06-06	2015-03-18	바이오노르 이뮤노 에이에스	백신
EA201492262A1 (ru)	2012-06-06	2015-08-31	Бионор Иммуно Ас	Конструкция пептидного каркаса
KR102110873B1 (ko)	2012-09-11	2020-05-14	온코세라피 사이언스 가부시키가이샤	Ube2t 펩티드 및 이를 포함하는 백신
EP2908851A1 (en)	2012-10-19	2015-08-26	Bavarian Nordic Inc.	Methods and compositions for the treatment of cancer
US9803021B2 (en)	2012-12-07	2017-10-31	The Regents Of The University Of California	CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP3421997B1 (en) *	2012-12-28	2020-06-17	Cellestis Limited	A cell mediated immune response assay
US10093745B2 (en)	2013-05-29	2018-10-09	The Regents Of The University Of California	Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2015007337A1 (en)	2013-07-19	2015-01-22	Bionor Immuno As	Method for the vaccination against hiv
EP3142689B1 (en)	2014-05-13	2020-11-11	Bavarian Nordic A/S	Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
CA2951616A1 (en)	2014-07-11	2016-01-14	Bionor Immuno As	Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US20210260181A1 (en) *	2014-09-16	2021-08-26	Altimmune, Inc	Coronavirus immunogenic compositions and uses thereof
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20180066018A1 (en) *	2015-03-11	2018-03-08	Board Of Regents Of The University Of Nebraska	Conformationally stable analogs of the response selective c5a agonist ep67
BR112017020058A2 (pt) *	2015-03-20	2018-06-05	Childrens Nat Medical Ct	processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células.
US20180140694A1 (en)	2015-05-04	2018-05-24	Bionor Immuno As	Dosage regimen for hiv vaccine
CN107847572A (zh)	2015-05-13	2018-03-27	艾吉纳斯公司	用于癌症治疗和预防的疫苗
CN116196426A (zh)	2015-07-16	2023-06-02	百欧肯治疗有限公司	治疗癌症的组合物及方法
CA3000776A1 (en) *	2015-10-06	2017-04-13	Invectys	Polyepitope constructs for use in immunotherapy
CA3014530A1 (en)	2016-02-23	2017-08-31	Biolinerx Ltd.	Methods of treating acute myeloid leukemia
CN105879058B (zh) *	2016-05-10	2017-11-14	华中科技大学	一种结核病基因药物及其制备方法
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
BR112019018748A2 (pt)	2017-03-11	2020-04-07	Selecta Biosciences Inc	métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
WO2019061297A1 (zh) *	2017-09-29	2019-04-04	苏州工业园区唯可达生物科技有限公司	一种cd4辅助性t细胞表位融合肽及其疫苗
MA52363A (fr)	2018-04-26	2021-03-03	Agenus Inc	Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
US20240269254A1 (en)	2018-10-05	2024-08-15	Bavarian Nordic A/S	Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist
CN111068069B (zh) *	2018-10-18	2022-05-20	中国医学科学院药物研究所	一种免疫靶向功能性脂质体及其制备方法与用途
AU2019385665A1 (en)	2018-11-20	2021-05-27	Bavarian Nordic A/S	Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40l
GB201907413D0 (en)	2019-05-24	2019-07-10	Univ Helsinki	Viral vector
EP4061406A1 (en)	2019-11-20	2022-09-28	Bavarian Nordic A/S	Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
EP4103587A1 (en)	2020-02-14	2022-12-21	Immunor AS	Corona virus vaccine
EP4103210A4 (en) *	2020-02-14	2024-03-20	Altimmune Inc	IMMUNOGENIC CORONAVIRUS COMPOSITIONS AND USES THEREOF
CN112980857A (zh) *	2021-04-26	2021-06-18	重庆医科大学附属儿童医院	一种编码分泌性野生型gaa蛋白的核苷酸组合物、腺相关病毒载体及其药物和应用
WO2023118508A1 (en)	2021-12-23	2023-06-29	Bavarian Nordic A/S	Recombinant mva viruses for intraperitoneal administration for treating cancer
EP4452306A1 (en)	2021-12-23	2024-10-30	Bavarian Nordic A/S	Therapy for modulating immune response with recombinant mva encoding il-12
WO2024121411A1 (en) *	2022-12-09	2024-06-13	Strike Pharma Ab	Optimized tag moiety
WO2024149832A1 (en)	2023-01-12	2024-07-18	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986007383A1 (en)	1985-06-04	1986-12-18	Biotechnology Research Partners, Ltd.	Autoantigen vaccines
US4772685A (en) *	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5126399A (en) *	1986-04-30	1992-06-30	Board Of Regents, The University Of Texas System	Methods and compositions for the preparation and use of site-directed immunologic reagents
JPH03504975A (ja) *	1988-06-14	1991-10-31	セル―エスシーアイ　コーポレイション	異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
ES2055785T3 (es) *	1989-01-17	1994-09-01	Eniricerche Spa	Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
IT1237764B (it) *	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) *	1993-08-26	1993-08-26	Mouritsen Og Elsner Aps	Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
JP3926839B2 (ja)	1993-09-14	2007-06-06	エピミューン，インコーポレイティド	万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5501063A (en)	1994-09-06	1996-03-26	Kimberly-Clark Corporation	Apparatus and method of reducing the force to expel a tampon from a tampon applicator and the applicator itself
AUPN015794A0 (en)	1994-12-20	1995-01-19	Csl Limited	Variants of human papilloma virus antigens
US6410690B1 (en) *	1995-06-07	2002-06-25	Medarex, Inc.	Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997041227A1 (en)	1996-05-01	1997-11-06	T Cell Sciences, Inc.	Plasmid-based vaccine for treating atherosclerosis
CA2261990A1 (en) *	1996-07-25	1998-02-05	Therion Biologics Corporation	Recombinant pox virus for immunization against tumor-associated antigens
AUPO390396A0 (en) *	1996-11-29	1996-12-19	Csl Limited	Novel promiscuous T helper cell epitopes
WO1998025574A2 (en) *	1996-12-10	1998-06-18	Sloan-Kettering Institute For Cancer Research	Stimulation of an immune response to differentiation antigen stimulated by altered antigen
EP1005374B1 (en)	1997-01-22	2007-04-18	Zycos Inc.	Microparticles for delivery of nucleic acid
GB9711957D0 (en)	1997-06-09	1997-08-06	Isis Innovation	Methods and reagents for vaccination
GB9717953D0 (en)	1997-08-22	1997-10-29	Smithkline Beecham Biolog	Vaccine
PT1584685E (pt)	1998-02-05	2011-06-17	Glaxosmithkline Biolog Sa	Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
WO1999056919A1 (de)	1998-04-30	1999-11-11	Manfred Schneider	Werkzeugmaschine mit werkzeugwechsel
KR100731820B1 (ko) *	1998-10-05	2007-06-25	파멕사 에이/에스	치료적 백신화를 위한 새로운 방법

1999
- 1999-10-05 KR KR1020017004399A patent/KR100731820B1/ko not_active IP Right Cessation
- 1999-10-05 PT PT99945967T patent/PT1117421E/pt unknown
- 1999-10-05 AT AT99945967T patent/ATE269100T1/de active
- 1999-10-05 SK SK427-2001A patent/SK4272001A3/sk unknown
- 1999-10-05 JP JP2000573386A patent/JP2002526419A/ja active Pending
- 1999-10-05 ES ES99945967T patent/ES2222728T3/es not_active Expired - Lifetime
- 1999-10-05 HU HU0103976A patent/HUP0103976A3/hu unknown
- 1999-10-05 MX MXPA01003503A patent/MXPA01003503A/es not_active Application Discontinuation
- 1999-10-05 CN CNB998117609A patent/CN1325115C/zh not_active Expired - Fee Related
- 1999-10-05 EP EP99945967.0A patent/EP1117421B2/en not_active Expired - Lifetime
- 1999-10-05 PL PL347977A patent/PL202399B1/pl not_active IP Right Cessation
- 1999-10-05 CZ CZ20011049A patent/CZ20011049A3/cs unknown
- 1999-10-05 EA EA200100425A patent/EA003634B1/ru not_active IP Right Cessation
- 1999-10-05 TR TR2001/00936T patent/TR200100936T2/xx unknown
- 1999-10-05 IL IL14186899A patent/IL141868A0/xx not_active IP Right Cessation
- 1999-10-05 CA CA2345817A patent/CA2345817C/en not_active Expired - Lifetime
- 1999-10-05 AU AU58510/99A patent/AU751709B2/en not_active Expired
- 1999-10-05 WO PCT/DK1999/000525 patent/WO2000020027A2/en not_active Application Discontinuation
- 1999-10-05 US US09/806,703 patent/US7005498B1/en not_active Expired - Lifetime
- 1999-10-05 EE EEP200100203A patent/EE200100203A/xx unknown
- 1999-10-05 NZ NZ511055A patent/NZ511055A/en not_active IP Right Cessation
- 1999-10-05 DE DE69918146T patent/DE69918146T2/de not_active Expired - Lifetime
2001
- 2001-03-28 NO NO20011586A patent/NO20011586L/no not_active Application Discontinuation
- 2001-05-04 HR HR20010319A patent/HRP20010319A2/hr not_active Application Discontinuation
2002
- 2002-02-09 HK HK02101047.9A patent/HK1039749B/zh not_active IP Right Cessation
2003
- 2003-05-19 US US10/441,779 patent/US7820633B2/en not_active Expired - Fee Related
2005
- 2005-08-11 US US11/202,516 patent/US7807441B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7820633B2 (en)	2010-10-26
JP2002526419A (ja)	2002-08-20
EP1117421B1 (en)	2004-06-16
CN1323217A (zh)	2001-11-21
EA003634B1 (ru)	2003-08-28
CA2345817C (en)	2013-02-12
NO20011586D0 (no)	2001-03-28
US7807441B2 (en)	2010-10-05
DE69918146D1 (de)	2004-07-22
EP1117421B2 (en)	2014-03-19
CZ20011049A3 (cs)	2002-08-14
HUP0103976A2 (hu)	2002-02-28
HUP0103976A3 (en)	2008-04-28
DE69918146T2 (de)	2005-07-07
WO2000020027A3 (en)	2000-10-12
PL347977A1 (en)	2002-05-06
TR200100936T2 (tr)	2001-08-21
US20040141958A1 (en)	2004-07-22
ES2222728T3 (es)	2005-02-01
HRP20010319A2 (en)	2002-06-30
ATE269100T1 (de)	2004-07-15
CN1325115C (zh)	2007-07-11
KR20010085894A (ko)	2001-09-07
EA200100425A1 (ru)	2001-10-22
AU5851099A (en)	2000-04-26
PL202399B1 (pl)	2009-06-30
CA2345817A1 (en)	2000-04-13
MXPA01003503A (es)	2005-01-14
PT1117421E (pt)	2004-11-30
AU751709B2 (en)	2002-08-22
HK1039749A1 (en)	2002-05-10
HK1039749B (zh)	2007-10-05
US7005498B1 (en)	2006-02-28
NO20011586L (no)	2001-05-31
SK4272001A3 (en)	2003-02-04
EP1117421A2 (en)	2001-07-25
US20060008465A1 (en)	2006-01-12
EE200100203A (et)	2002-10-15
NZ511055A (en)	2003-10-31
WO2000020027A2 (en)	2000-04-13
KR100731820B1 (ko)	2007-06-25

Publication	Publication Date	Title
IL141868A0 (en)	2002-03-10	Novel methods for therapeutic vaccination
BR9306984A (pt)	1999-01-12	Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
DE69929444D1 (de)	2006-04-06	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
ME00183B (me)	2011-02-10	Novi postupak za deregulaciju amiloida
HUP0101464A2 (hu)	2001-08-28	Mutáns rekombináns allergének
HK1093314A1 (en)	2007-03-02	Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
AU1800597A (en)	1997-08-28	Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
DE60325696D1 (de)	2009-02-26	Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
BR0111834A (pt)	2003-07-08	Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
DE69836520D1 (de)	2007-01-11	Clostridium perfringens Impfstoff
WO2003059379A3 (en)	2003-12-04	Immunogenic carcinoembryonic antigen (cea)
FI924222A (fi)	1992-09-21	Gp75 som ett tumoervaccin mot melanoma
WO2000012122A3 (de)	2000-06-22	Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
EP1502602A3 (en)	2006-05-17	Methods for therapeutic vaccination
TNSN08184A1 (en)	2009-10-30	Chimeric antigens and vaccines
SE9903534D0 (sv)	1999-09-30	Vaccin
CN1056816A (zh)	1991-12-11	改良的疫苗组合物
YU24401A (sh)	2005-07-19	Novi postupci za terapeutsku vakcinaciju
BR9709993A (pt)	1999-08-10	Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
IL149415A0 (en)	2002-11-10	Adjuvanted genetic vaccines
WO2002000250A3 (en)	2002-10-31	Hiv-1 vaccines and screening methods therefor
BR0009746A (pt)	2002-01-22	Molécula de veìculo, composição imunogênica, polipeptìdeo, método para tratar um indivìduo, e, plasmìdeos pebl1-pv e pviii
BR9905780A (pt)	2001-04-24	Antìgenos vacinais de leptospira para prevenção da laptospirose
EA200500480A1 (ru)	2005-08-25	Иммунизация против аутологичного грелина

Legal Events

Date	Code	Title
2006-09-05	KB	Patent renewed
2010-05-17	KB	Patent renewed
2013-10-31	KB	Patent renewed
2017-09-28	KB	Patent renewed
2020-05-31	EXP	Patent expired